Editorial label review
Alloy side effects: insomnia
Primary formulary: Estradiol (oral and patch) + oral micronized progesterone; oxybutynin ER for vasomotor symptoms
Quick answer
Insomnia shows up on the FDA labels for the active ingredients Alloy prescribes — Estradiol (oral and patch) + oral micronized progesterone. This page walks through the labelled frequency ranges, what to watch for, and when to call your clinician.
What Alloy prescribes and why it matters for insomnia
Alloy prescribes FDA-approved bioidentical estradiol and oral micronized progesterone, plus oxybutynin ER as a non-hormonal option for vasomotor symptoms. Because Alloy prescribes FDA-approved active ingredients, the labelled adverse-reaction tables from those medications describe the frequencies you should expect. Paroxetine (Brisdelle) carries the highest label-level insomnia signal across these programmes.
Common label-level side effects
Sourced from Section 6 (Adverse Reactions) of each FDA-approved PIL.
- Insomnia is listed at 2–6% in Section 6 of most estradiol PIL adverse-reaction tables
- Brisdelle (paroxetine 7.5 mg) PIL lists insomnia at 15–20% — a Midi and Hims & Hers non-HRT consideration
- Fezolinetant (Veozah) PIL lists insomnia at low frequency in Section 6
Serious label-level warnings
Drawn from Section 5 (Warnings and Precautions) of the FDA-approved PILs — including the estradiol boxed warning where applicable.
- Insomnia with rapidly worsening depression or new suicidal thoughts on paroxetine — FDA class boxed warning applies
- Insomnia paired with chest pain or palpitations — cardiovascular signals on the estradiol boxed warning
When to contact your clinician
Contact your clinician if insomnia is paired with new suicidal thoughts on paroxetine, or with chest symptoms on estradiol — both labels require prompt review.
Call 911 if you develop chest pain, one-sided weakness, sudden severe headache, vision or speech change, or shortness of breath — per the estradiol PIL boxed warning for cardiovascular events.
What to ask your provider
- “Which SKU in the Alloy formulary am I on, and what is its labelled frequency for insomnia?”
- “Is my insomnialikely a labelled adverse reaction, or something separate that needs its own workup?”
- “Would a different delivery route (patch vs. pill, oral vs. transdermal) change my expected frequency?”
- “What is the plan if insomniadoes not settle within 2–3 cycles?”
Related editorial reading
- Full editorial review of Alloy — formulary, pricing, and clinician model.
- Is insomnia caused by menopause itself? — how the transition presents on its own.
- Estradiol medication page — mechanism, dosing, and full PIL notes.
- Progesterone medication page — secondary ingredient in Alloy's formulary.
- Browse all side-effect matrix pages — 4 brands × 15 symptoms.
Frequently asked questions
- How often does insomnia happen on Alloy?
- Alloy's primary regimen — Estradiol (oral and patch) + oral micronized progesterone; oxybutynin ER for vasomotor symptoms — carries the FDA-labelled adverse-reaction frequencies for insomnia described on this page. Ranges vary from < 1% to 45% depending on the specific active ingredient and delivery route. See the sources block for the exact PIL tables.
- When should I stop Alloy because of insomnia?
- Talk to your clinician immediately if you meet any of the "when to contact" criteria on this page — most estradiol PIL Section 5 warnings require prompt reassessment. Do not stop hormone therapy without medical input; abrupt discontinuation can trigger rebound symptoms.
- Is insomnia on the FDA label for Alloy's medications?
- Paroxetine (Brisdelle) carries the highest label-level insomnia signal across these programmes.
- Is insomnia caused by menopause itself?
- Insomnia can appear during the menopause transition for reasons unrelated to hormone therapy. Our /does-menopause-cause/insomnia explainer covers what the underlying biology is and how clinicians disentangle the transition from the treatment.